Citations

Mayo Clinic

Showing 10 of 108602 citations.

Abstract SY30-03: Composing each patient’s equation: Unraveling brain tumor complexity by integrating multi-regional image-localized biopsies
Swanson, Kristin R. , Swanson, Kristin R

Cancer Research | April 4, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: SY30-03-SY30-03

10.1158/1538-7445.am2023-sy30-03 Get It

Abstract Glioblastoma is a uniquely challenging and aggressive cancer that is practically considered uniformly fatal. This aggressiveness is driven by heterogeneity between and within patients and the diffuse invasion of tumor cells deep into the normal appearing brain tissue surrounding the frank tumor abnormality. Mathematical neuro-oncology (MNO) is a burgeoning field that seeks to bring together individual patient data (like patient imaging, tissue biopsies etc) to tune mathematical models that accurately predict and quantify response to treatments for each patient. These mathematical models use both mechanistic “weather forecasting” methods and artificial intelligence pattern recognition methods. Ultimately, these models form the basis of modern "precision medicine" approaches to tailor therapy in a patient-specific manner. These models can be used to overcome the limited ability of imaging to accurately detect tumor cells, improve prognostic predictions, stratify patients, and assess treatment response in silico in the construction of effective clinical trials and treatment protocols, thus accelerating the pace of clinical research. This presentation will focus on the growing translation of MNO to clinical neuro-oncology highlighting burgeoning insights into sex differences in tumor incidence, outcomes, and response to therapy. Specifically, I will discuss 1) use of our 4,500+ patient cohorts of 100,000+ annotated serial MR imaging data to develop digital twins accurately predict response and outcomes in patients and 2) our unique collection of 1000+ image-localized biopsies across nearly 200 patients to detect sex-distinct patterns of mapping between regional imaging features and underlying regional tumor biology. We will demonstrate the value of these novel combined resources in predicting response to treatment for EGFR-targeted therapies in 3 clinical trials and differentiating response to novel dendritic cells vaccines and CAR T-cell therapies in 2 additional clinical trials. Taken together, these complimentary approaches provide a platform to incorporate inter- and intra- tumoral heterogeneity into accurate predictive models that advance precision oncology for glioblastoma patients. Citation Format: Kristin R. Swanson. Composing each patient’s equation: Unraveling brain tumor complexity by integrating multi-regional image-localized biopsies. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr SY30-03.
Abstract 1689: The role of circular RNAs in triple negative breast cancer and chemotherapy resistance
Emch, Michael J. , Yu, Jia , Wang, Liewei , Hawse, John R. , Wang, Xiyin , Tang, Xiaojia , Kalari, Krishna R. , Goetz, Matthew P.

Cancer Research | April 4, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 1689-1689

10.1158/1538-7445.am2023-1689 Get It

Abstract Background: Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer-related death among women worldwide. Triple negative breast cancer (TNBC) represents 15-20% of all breast cancers and is an aggressive subtype. Chemotherapy-based treatments remain the standard of care for TNBC. Unfortunately, chemotherapy resistance is common, and for these patients, outcomes are poor and alternative treatment strategies remain an unmet need. circRNAs are a newly identified class of noncoding RNA molecules with covalently closed circular structures. An increasing number of recent studies including ours have indicated that circRNAs play crucial roles in regulating tumor development and chemoresistance. However, the role of circRNAs in the process of chemotherapy resistance and TNBC progression is not clear. Materials and Methods: As a first step towards identifying circRNAs that participate in the development of chemoresistance in TNBC cells, and to determine if targeting such circRNAs is a novel and efficacious therapeutic strategy, doxorubicin-resistant (Doxo-R), paclitaxel-resistant (PTX-R), and double-resistant (DP-R) cell lines were generated from MDA-MB-231. Human circRNA microarrays were utilized to profile the expression of approximately 14,000 known circRNAs in normal breast tissue, matched patient-derived xenografts (PDX) generated prior to and following neoadjuvant chemotherapy (NAC), and TNBC chemosensitive and chemoresistant cell lines. Top hits were validated using RT-PCR. Results: circRNA microarray profiling identified 429 and 310 transcripts differentially expressed in doxorubicin and paclitaxel resistant cells, respectively, compared to parental chemosensitive cell lines (|FC| ≥ 1.5; p value < 0.05). In comparison to pre-NAC derived xenografts, 1,396 circRNAs were dysregulated among post-NAC PDX models. Further, three circRNAs (hsa_circ_001388, hsa_circ_104652, and hsa_circ_061260) were upregulated in Doxo-R, PTX-R, and post-NAC PDX samples compared to their respective controls. Among these three circRNAs, hsa_circ_001388 (also known as circNSD2) was the only transcript also predicted to be translated into a novel and uncharacterized protein given the presence of a high confidence translation initiation site and IRES sequence. Ongoing studies are aimed at determining the role of circNSD2 protein in breast cancer carcinogenesis, progression, and response to standard of care chemotherapeutics and the mechanistic process by which this protein functions. Additionally, the efficacy of specifically targeting this circRNA as a novel therapeutic approach is being explored. Conclusions: Increasing knowledge of the important functions of circRNAs underlying drug resistance will provide new opportunities for developing efficacious therapeutic strategies and prognostic/predictive biomarkers for TNBC. Citation Format: Xiyin Wang, Michael J. Emch, Xiaojia Tang, Jia Yu, Krishna R. Kalari, Liewei Wang, Matthew P. Goetz, John R. Hawse. The role of circular RNAs in triple negative breast cancer and chemotherapy resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1689.
Abstract 6208: Targeting DNA polymerase theta and ATM leads to synergistic killing of mantle cell lymphoma cells
Abeykoon, Jithma P. , Parmar, Kalindi , Wu, Xiaosheng , D’Andrea, Alan D. , D'Andrea, Alan , Asada, Shuhei , Witzig, Thomas E. , Shapiro, Geoffrey I.

Cancer Research | April 4, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 6208-6208

10.1158/1538-7445.am2023-6208 Get It

Abstract Introduction: Rapid cell proliferation requires intact and faithful DNA damage repair mechanisms. DNA polymerase theta (POLQ) plays a key role in repairing DNA double-strand breaks through the microhomology-mediated end-joining (MMEJ), which is one of the three main pathways involved in repairing replication-induced double-strand breaks. Limited data have suggested that concurrent depletion of POLQ and ataxia-telangiectasia mutated (ATM) could be embryonic lethal. Hence, this phenomenon has the potential to be exploited for therapeutic benefit in cancers where ATM mutations are commonly seen. Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma marked by (11;14) translocation with ATM alterations seen in 40-50% of patients. There is an unmet need to find novel therapeutic strategies, especially in relapsed and/or refractory (R/R) MCL. Here, we investigated whether targeting POLQ and ATM could be a potential therapeutic strategy in MCL. Methods: In vitro studies were conducted by using MCL cell lines. CRISPR-Cas9 system was used to genetically deplete POLQ and ATM genes and sgRNAs co-expressing fluorescence markers were used to track the cell population with respective genotypes over time. Cell viability was assessed by CellTiter-Glo assay and flow cytometry. All cell lines were profiled for ATM expression and activity. A p-value of < 0.05 was considered statistically significant. The combination index of <1 was defined as synergistic. Results: CRISPR-Cas9-mediated depletion of POLQ significantly decreased cell proliferation in multiple MCL cell lines. In particular, Granta-519, which possesses a single copy of kinase-dead ATM that is reduced in expression, was most sensitive to POLQ depletion. Concurrent genetic depletion of ATM and POLQ resulted in a synergistic antiproliferative effect in ATM-proficient MCL cell lines. Subsequently, this cellular phenotype caused by the genetic intervention was recapitulated by using two POLQ inhibitors (novobiocin and ART558) and an ATM inhibitor (AZD0156). In vitro, single-agent treatment with novobiocin or ART558 caused a significant cytotoxic effect at physiologically relevant concentrations in ATM-deficient cells and co-treatment of novobiocin or ART558 with AZD0156 was synergistic in killing ATM-proficient MCL cells. Importantly, POLQ inhibitors significantly decreased the cell viability of MCIR1, which is an ibrutinib-resistant MCL cell line. Mechanistically, novobiocin or ART558 treatment induced gH2AX and cleaved PARP upregulation, which was further enhanced by ATM depletion, suggesting that co-inhibition of POLQ and ATM caused apoptosis due to the accumulation of unrepaired DNA damage. Conclusion: POLQ is a promising target in MCL, especially in ATM-deficient setting. In ATM-proficient MCL, targeting ATM and POLQ is synergistic. Our data has the potential to uncover novel biomarker-driven drug therapy of POLQ inhibitors in R/R MCL. Citation Format: Jithma Prasad Abeykoon, Shuhei Asada, Kalindi Parmar, Xiaosheng Wu, Thomas Witzig, Geoffrey Shapiro, Alan D. D'Andrea. Targeting DNA polymerase theta and ATM leads to synergistic killing of mantle cell lymphoma cells. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6208.
Abstract 1153: IL-4 depletion leads to the improvement of CART cell therapy
Stewart, Carli M. , Ogbodo, Ekene J. , Yun, Kun , Sirpilla, Olivia , Girsch, James H. , Huynh, Truc , Mattie, Mike , Filosto, Simone, Stewart, Carli , Cox, Michelle J. , Sakemura, Reona , Can, İsmail , Roman, Claudia Manriquez , Siegler, Elizabeth L. , Kim, Jaeyeon , Scholler, Nathalie , Kenderian, Saad S.

Cancer Research | April 4, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 1153-1153

10.1158/1538-7445.am2023-1153 Get It

Abstract While chimeric antigen receptor T-cell therapy targeting CD19 (CART19) has shown remarkable success in the treatment of hematological malignancies, the durable response rates remain approximately 40% and there are limited solutions for CART cell therapy in the treatment of solid tumors. To further understand mechanisms of resistance, including CART cell exhaustion, we employed three independent approaches: 1) RNA and ATAC sequencing on unstimulated vs. exhausted healthy donor CART19 cells by utilizing an in vitro model for exhaustion, 2) RNA and ATAC sequencing on pre-infusion CART19 cell products from responders and non-responders in the Zuma-1 clinical trial that led to the FDA approval of axi-cel CART19 therapy, and 3) a genome-wide CRISPR knockout screen in healthy donor CART19 cells using our in vitro model for exhaustion. In each of these approaches, IL-4 was identified as a regulator of CART cell dysfunction. In approach 1, ingenuity pathway analysis of genes that were both differentially accessible and expressed in exhausted compared with unstimulated CART19 cells revealed IL-4 as a top upstream regulator (p = 5E-6). In approach 2, IL-4 was one of two genes that were both upregulated and more accessible in CART19 cell products from non-responders (p < 5E-2). Finally, in approach 3, gene ontology enrichment analysis of genes that were positively selected during the genome-wide CRISPR knockout screen, revealed regulation of the IL-4 pathway as one of the top affected pathways (p = 1E-4). Together, our data indicates a role for IL-4 in CART cell dysfunction caused by exhaustion. Investigating this mechanism further, we saw an increase in the production of IL-4 as CART cells became exhausted (p = 4E-3). Treatment of CART19 cells with human recombinant IL-4 (hrIL-4) resulted in dysfunction as evident by a decrease in antigen specific cytotoxicity (p = 4E-3) and proliferative ability (p= 6.5E-2), as well as exhaustion-specific signs of dysfunction such as an increase in the expression of the inhibitory receptor, TIM-3 (p = 3E-3) and an increase in the transcription of the exhaustion-related transcription factor EOMES (p = 1E-2). Finally, we tested whether IL-4 neutralization enhances CART19 cell functions. Using a CD19+ JeKo-1 xenograft mouse model, we compared the combination treatment of CART19 cells and an IL-4 neutralizing monoclonal antibody (10 mg/Kg, clone # MP4-25D2) to CART19 cells and an IgG control. IL-4 neutralization in combination with CART19 cells resulted in reduced tumor burden (p = 4.6E-2), increased CART cell proliferation (p = 8E-3), and prolonged overall survival (p= 5E-2). In summary, our data indicates that 1) IL-4 induces CART cell dysfunction through a state of exhaustion and 2) IL-4 neutralization with a monoclonal antibody enhances CART cell therapy. As such, this novel combination therapy holds the potential to be translated to the clinic to improve durable responses from CART cell therapy. Citation Format: Carli Stewart, Michelle J. Cox, Reona Sakemura, Ekene J. Ogbodo, Ismail Can, Claudia Manriquez Roman, Kun Yun, Olivia Sirpilla, James H. Girsch, Truc Huynh, Elizabeth L. Siegler, Jenny J. Kim, Mike Mattie, Nathalie Scholler, Simone Filosto, Saad S. Kenderian. IL-4 depletion leads to the improvement of CART cell therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1153.
Abstract 1360: Spatial image analysis of tumor-infiltrating lymphocytes on gastric cancer to predict anti-PD1 inhibitor response
Park, Sunho , Kim, In-Ho , Hwang, Tae Hyun , Lee, Sanghoon , Cheong, Jae‐Ho , Wang, Sam C. , Porembka, Matthew R , Lee, Sung Hak

Cancer Research | April 4, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 1360-1360

10.1158/1538-7445.am2023-1360 Get It

Abstract Background: The Tumor Immune microenvironment (TME) plays an important role in tumor development, progression, and treatment response. Recent studies show that spatial heterogeneity of Tumor-Infiltrating Lymphocytes (TILs), consisting of lymphocytic cell populations, is an important histopathologic feature and a powerful prognostic and predictive marker correlating with cancer progression and treatment response. Detecting and quantifying TIL density in Whole Slide Images (WSIs) is, however, labor-intensive, and it is difficult to assess differences in the composition of immune cells. Therefore, it remains a challenge to establish the analysis of TILs in the complex TME. We present an automated spatial image analysis of TILs on gastric cancer to address cancer immunotherapy. Method: 1,031WSIs of hematoxylin and eosin-stained (H&E) formalin-fixed paraffin-embedded (FFPE) sections from four patient cohorts: TCGA-STAD (329), Yonsei-1 (620 patients), Yonsei-2 (45), and St. Mary (37), were analyzed. Two treatment groups in response were classified as CR + PR, while another two treatment groups in non-response were classified as PD + SD. H&E stained WSIs were normalized using the Reinhard normalization method at 20X magnification for reducing the color variability of the stained tissue images. We used U-Net architecture to predict the normalized H&E stained WSIs. Three U-Net models were trained for predicting tumor, TILs, and stroma, using Adam optimizer, 1e-4 learning rate, a binary loss function, L2 regularization, and 50 epochs. The normalized H&E stained WSIs were predicted using the trained U-Net models. Spatial analysis of TILs was conducted on the predicted WSIs. Regional quantification of TILs was performed by two immune phenotype groups: immune-immersed (TILs enriched in tumor cells) and immune-excluded (TILs not enriched in tumor cells but in stromal cells). Kaplan-Meier with a log-rank test was used to evaluate the survival differences between the groups. Results: In TCGA-STAD, the proportion of immune-immersed composition is significantly different from the immune-excluded (p-value 0.05). In Yonsei-1, the immune-excluded composition is significantly different among the three risk groups (p-value 3e-05). In the Yonsei-2 and St. Mary cohorts, including anti-PD1 treated gastric cancer patients, the immune-immersed composition is significantly different between two response groups (p-value 0.007) and represented the diagnostic accuracy (AUROC: 0.78) on CR + PR groups. Conclusion: These findings suggest that the proposed TIL quantification in the complex TME is strongly associated with patient prognosis and anti-PD1 treatment response in gastric cancer. Citation Format: Sanghoon Lee, Sunho Park, Jae-Ho Cheong, Sam C. Wang, Matthew R. Porembka, In-Ho Kim, Sung Hak Lee, Tae Hyun Hwang. Spatial image analysis of tumor-infiltrating lymphocytes on gastric cancer to predict anti-PD1 inhibitor response [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1360.
Abstract 4996: Axl inhibition sensitizes cholangiocarcinoma cells to cytotoxic chemotherapy
Takaichi, Shohei , Carlson, Danielle M. , Daher, Alaa Abou , Werneburg, Nathan W., Wu, Xinyan , Mun, Dong‐Gi , Tomlinson, Jennifer L. , Abdelrahman, Amro M. , Carlson, Danielle Marie , Pandey, Akhilesh , Gores, Gregory J. , Smoot, Rory L.

Cancer Research | April 4, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 4996-4996

10.1158/1538-7445.am2023-4996 Get It

Abstract Background: Cholangiocarcinoma (CCA) is a lethal disease with limited therapeutic options. We have previously discovered LCK driving signaling through AXL, a TAM receptor tyrosine kinase (RTK), by phosphoproteomic analysis of CCA (J Hepatol 2022). AXL mediates acquired drug resistance in solid cancers. However, the exact role of AXL in CCA still remains to be elucidated. Here, we investigated the significance of AXL expression as a potential therapeutic target in CCA and the role of phosphorylated AXL Y866. Methods: We first evaluated the expression levels of AXL in CCA and its associations with patient outcomes using The Cancer Genome Atlas (TCGA) database. Next, to evaluate whether AXL inhibition sensitizes CCA cells to gemcitabine and cisplatin (GemCis) therapy, AXL downregulation was achieved via the siRNA approach and the selective inhibitor bemcentinib. We examined the 50% inhibitory concentration (IC50) value of HuCCT1, a well-characterized CCA cell line, on GemCis therapy with or without AXL knockdown using cell viability assay. Then we assessed the efficacy of the combinatorial therapy of GemCis and bemcentinib utilizing Calcusyn software. Apoptosis was evaluated by Annexin V assay. In vivo efficacy was assessed using an SB-1 (murine CCA cell line) and a syngeneic murine model of CCA treated with vehicle, GemCis, bemcentinib, and the combination of GemCis and bemcentinib. Finally, to investigate the role of AXL Y866 in CCA, we performed BioID to identify and compare the interactomes of AXL WT and AXL Y866F in HuCCT1 cells. Results: In the TCGA cohorts, AXL is significantly expressed in CCA (P < 0.01), and disease-free survival and overall survival in the low AXL expression group are significantly longer than those in the high AXL expression group (P = 0.04, 0.01). In in vitro study, the IC50 value of GemCis was decreased from 685nM to 129nM after AXL knockdown. A synergistic effect was observed with CI = 0.17 and Fa = 0.50 in the combinatorial therapy. The combinatorial therapy caused significantly increased apoptosis compared to GemCis or bemcentinib alone (P < 0.01, P < 0.01). In in vivo study, the combinatorial therapy significantly suppressed the tumor growth compared to GemCis or bemcentinib alone (P = 0.04, 0.01), and the expression levels of Ki67 and the phosphorylation levels of PEAK1 decreased in the combinatorial therapy group compared to other groups in immunostaining examination. In BioID experiments, among the 222 proteins detected in both AXL WT and AXL Y866F interactomes, PEAK1 kinase, which localizes to actin cytoskeleton and focal adhesions, was the kinase most affected by AXL Y866. In gene ontology analysis to characterize the interactome of AXL Y866, cell-cell adhesion and focal adhesion-related proteins were enriched. Conclusions: AXL inhibition sensitizes CCA cells to cytotoxic chemotherapy in the preclinical model. AXL Y866-PEAK1 signaling axis is a potential target for the treatment of CCA. Citation Format: Shohei Takaichi, Dong-Gi Mun, Jennifer L. Tomlinson, Amro M. Abdelrahman, Danielle M. Carlson, Alaa Abou Daher, Nathan W. Werneburg, Xinyan Wu, Akhilesh Pandey, Gregory J. Gores, Rory L. Smoot. Axl inhibition sensitizes cholangiocarcinoma cells to cytotoxic chemotherapy. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4996.
Abstract 5621: Multi-parametric MRI maps regional heterogeneity of high grade glioma phenotypes
Flick, Matthew , Weiskittel, Taylor M. , Meng-Lin, Kevin, Blomquist, Mylan, Wang, Luija, Sereduk, Christopher, León, Gustavo De , Nespodzany, Ashley , Urcuyo, Javier , Gonzalez, Ashlynn, Singleton, Kyle , Anil, Aliya , Simmineh, Natenael, Lewis, Erika , Patel, Reyna A., Wang, Panwen , Eschbacher, Jennifer , Smith, Kris A. , Bendok, Bernard R. , Zimmerman, Richard S. , Krishna, Chandan , Patra, Devi Prasad, Lyons, Mark , Neal, Matthew T. , Donev, Kliment , Mrugała, Maciej M. , Porter, Alyx B. , Beeman, Scott C. , Lasorella, Anna , Quarles, C. Chad , Tran, Nhan L. , Hu, Leland , Tran, Nhan L , D’Angelo, Fulvio , Caruso, Francesca Pia , Ensign, Shannon P. Fortin , Sereduk, Chris , Leon, Gustavo De, Curtin, Lee , Noviello, Teresa , Wang, Junwen , Hawkins‐Daarud, Andrea , Jackson, Pamela , Nakaji, Peter , Patel, Naresh P. , Zhou, Yuxiang , Baxter, Leslie C. , Plaisier, Christopher L. , Li, Jing , Li, Hu, Swanson, Kristin R , Ceccarelli, Michele , Iavarone, Antonio

Cancer Research | April 4, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 5621-5621

10.1158/1538-7445.am2023-5621 Get It

Abstract High grade glioma (HGG) represents a group of devastating diseases with dismal prognosis. Surgical resection of the contrast enhancing (CE) region of HGG remains the mainstay of treatment, but recurrence inevitably arises from the unresected non-contrast enhancing (NE) region, surgically inaccessible due to cancer cell invasion into healthy brain tissue. Due to its critical role in recurrence, understanding of the NE region is central to the improvement of clinical outcomes. We reveal the biological characteristics of this region through image localized multi-regional sampling. We linked microenvironmental characteristics measured by multi-parametric MRI to genomic mutations and transcriptional phenotypes using mixed effect modeling which allowed us to control for individualized patient effects. We first confirmed that T2 is a significant indicator of IDH mutation status in the NE region, being the first description of such a relationship in a HGG cohort. We found the combination of EGFR amplification and CDKN2A homozygous loss was associated with a significantly lower mean diffusivity (MD) compared to double wild type tumors in the NE region, indicating the presence of greater cellular packing and proliferation in EGFR amplification/CDKN2A loss regions. Finally, using single cell pathway based tumor classifications, we showed that nK2, a DSC-MRI metric representing cell size heterogeneity, correlated positively with neuronal signature and negatively with glycolytic/plurimetabolic signature within the NE tumor, indicating that glycolytic/plurimetobolic tumors possessed a high amount of cell size heterogeneity compared to neuronal samples. This hypothesis was supported using digital reference object (DRO) modeling which confirmed that cell size and heterogeneity drove the differential nK2 signal between neuronal and glycolytic/plurimetabolic samples. We identified immune cell infiltrate as one possible mechanism of increased cell size heterogeneity using transcriptomic signature analysis which found more immune cell signatures within glycolytic/plurimetobolic tumors compared to neuronal. Collectively this study demonstrates the central role of multi-parametric MRI as a non-invasive measure of tumor biology and a tool for understanding the clinically critical NE region which can then inform new therapies targeting this region of HGG recurrence. Citation Format: Matthew Flick, Taylor Weiskittel, Kevin Meng-Lin, Fulvio D'Angelo, Francesca Caruso, Shannon Ensign, Mylan Blomquist, Luija Wang, Christopher Sereduk, Gustavo De Leon, Ashley Nespodzany, Javier Urcuyo, Ashlynn Gonzalez, Lee Curtin, Kyle Singleton, Aliya Anil, Natenael Simmineh, Erika Lewis, Teresa Noviello, Reyna Patel, Panwen Wang, Junwen Wang, Jennifer Eschbacher, Andrea Hawkins-Daarud, Pamela Jackson, Kris Smith, Peter Nakaji, Bernard Bendok, Richard Zimmerman, Chandan Krishna, Devi Patra, Naresh Patel, Mark Lyons, Matthew Neal, Kliment Donev, Maciej Mrugala, Alyx Porter, Scott Beeman, Yuxiang Zhou, Leslie Baxter, Christopher Plaisier, Jing Li, Hu Li, Anna Lasorella, Chad Quarles, Kristin Swanson, Michele Ceccarelli, Antonio Iavarone, Nhan Tran, Leland Hu. Multi-parametric MRI maps regional heterogeneity of high grade glioma phenotypes. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5621.
Abstract 6523: A case of stage I HPV-mediated oropharyngeal squamous cell carcinoma (SCC) diagnosed using a multi-cancer early detection (MCED) test
Vittone, Janet L., Feygin, Julia, Carey, Jason

Cancer Research | April 4, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 6523-6523

10.1158/1538-7445.am2023-6523 Get It

Abstract There are no routine screening tests for head and neck (H&N) cancers, which account for approximately 4% of all cancers in the US. Risk factors for oropharyngeal cancer include smoking and human papillomavirus (HPV) infection. An MCED test that uses a cell-free DNA-based targeted methylation assay and machine learning classifiers to detect a shared cancer signal and predict the cancer signal origin (CSO) is available as a complement to existing single-cancer screening tests. If a cancer signal is detected, the positive result is reported with 1 or 2 CSO prediction(s). We report here a tonsil cancer case detected using an MCED test and review the CSO-guided diagnostic journey. An asymptomatic 74-year-old White male (BMI: 29.9 kg/m2) with history of chronic lymphocytic leukemia (CLL; Rai stage 0; 13q, CD38, and ZAP-70 negative; no treatment was needed) 17 years prior and papillary thyroid cancer (stage IVa; pT3N1bM0; thyroidectomy and radiation therapy; no recurrence) 8 years prior was screened using the MCED test. Patient had an elevated PSA level (9-10 ng/mL) and was a nonsmoker. Fifteen days after a blood sample was collected for analysis, a positive test result (CSO prediction=H&N) was communicated to the patient (Day 1). PET showed abnormal uptake in the right tonsil (Day 28). The patient was referred for an ENT consult and underwent a right lymph node biopsy (Day 54). The biopsy showed invasive moderately differentiated SCC, non-keratinizing, forming a 3 × 2.1 × 1.2 cm mass (Day 57). Patient underwent right tonsillectomy (the surgical margins were negative for invasive or in situ carcinoma) and lymph node dissection (Day 57). The cancer was diagnosed as HPV-mediated p16+, pT2, pN1, cM0 (stage I) SCC of the oropharynx (Day 57). No chemotherapy or radiation was required due to the early stage of detection. The patient will follow-up with ENT and radiation oncology. The MCED test detected a cancer signal and predicted an accurate CSO for an asymptomatic individual with stage I HPV-mediated oropharyngeal SCC. Notably, despite a history of CLL and an elevated PSA level, the test accurately predicted CSO leading to a directed workup diagnosing asymptomatic cancer in less than 2 months, while the cancer was still at stage I. In the case-control Circulating Cell-free Genome Atlas study, the MCED test sensitivity to detect a cancer signal was 63% in stage I H&N cancer. The use of this MCED test led to detection of cancer in a patient with CLL history and treatment (surgery without complications and without chemotherapy or radiation) with curative intent. Citation Format: Janet Vittone, Julia Feygin, Jason Carey. A case of stage I HPV-mediated oropharyngeal squamous cell carcinoma (SCC) diagnosed using a multi-cancer early detection (MCED) test [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6523.
Abstract 3031: Pilot study of EGFR inhibition with erlotinib in liver fibrosis for hepatocellular carcinoma prevention
Zahrieh, David M. , Flotte, Thomas J. , Della’Zanna, Gary , Tanabe, Kenneth K. , Strand, Carrie , Hoshida, Yujin , Umar, Asad , Limburg, Paul J.

Cancer Research | April 4, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 3031-3031

10.1158/1538-7445.am2023-3031 Get It

Abstract BACKGROUND: Effective approaches for prevention of hepatocellular carcinoma (HCC) will have a significant impact on HCC-related mortality. Data from preclinical models strongly support epidermal growth factor receptor (EGFR) as a target for chemoprevention of HCC. Erlotinib is a small-molecular EGFR tyrosine kinase inhibitor that is FDA-approved for cancer treatment. The side effects of erlotinib observed in patients receiving the oncology dose (150 mg/day) render it unacceptable as a chemoprevention agent at this dose. OBJECTIVE: The objective of this clinical trial was determination of a safe and minimum effective dose of erlortinib for which a ≥50% reduction phospho-EGFR immunohistochemical staining in the liver was observed. RESULTS: 46 participants were pre-registered and 25 participants were registered in this multicenter trial. In a dose de-escalation trial design, cohorts of participants received a 7 day course of erlotinib 75 mg/day, 50 mg/day or 25 mg/day with liver tissue acquisition prior to and after erlotinib. A ≥50% reduction phospho-EGFR immunohistochemical staining in the liver was observed in a minimum of 40% of participants at each of the dose levels. Erlotinib was very well tolerated with few side effects observed, particularly at the dose of 25 mg/day. A favorable modulation of the Prognostic Liver Signature was observed in participants that received the higher erlotinib doses (50 and 75 mg/day). CONCLUSION: These data support the selection a dose of 25 mg/day of erlotinib for a longer intervention to assess for evidence of efficacy as an HCC chemoprevention drug. Citation Format: Kenneth K. Tanabe, David Zahrieh, Carrie A. Strand, Yujin Hoshida, Thomas J. Flotte, Gary Della’Zanna, Asad Umar, Paul Limburg. Pilot study of EGFR inhibition with erlotinib in liver fibrosis for hepatocellular carcinoma prevention [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3031.
Abstract 3039: Evaluation of intra-tumoral pks+ E. coli, enterotoxigenic B. fragilis and Fusobacterium nucleatum, overall and in early onset disease, in colorectal cancer cases
Hullar, Meredith A.J. , Curtis, Keith R. , Harrison, Tabitha A. , Steinfelder, Robert S. , Berndt, Sonja I. , Figueiredo, Jane C. , French, Amy J. , Melaku, Johannes, Ugai, Tomotaka, Qu, Chenxu, Thibodeau, Steven, Zaidi, Syed Hassan Ejaz , Phipps, Amanda I. , Peters, Ulrike , investigators, on behalf of GECCO and CCFR, Harrison, Tabitha A , Lin, Yi , Buchanan, Daniel D. , Chan, Andrew T. , Drew, David A., Jenkins, Mark A. , Moreno, Vı́ctor , Ugai, Tomotaka , Ogino, Shuji , Qu, Conghui , investigators, on behalf of GECCO and CCFR

Cancer Research | April 4, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 3039-3039

10.1158/1538-7445.am2023-3039 Get It

Abstract Background: Colorectal cancer (CRC) incidence has increased in those 50 years or younger compared to older individuals in recent decades. While the intra-tumoral microbiome is a potent facilitator of tumorigenesis, the role of the microbiome in early onset (eo)CRC is unclear. Identification of the intra-tumoral microbiome may enhance prediction of adverse outcomes to improve survival of CRC overall age groups and eoCRC. Methods: We performed targeted sequencing of tumor and matched normal DNA samples from 3695 colorectal cancer cases within the Genetics and Colorectal Cancer Consortium (GECCO) and the Colon Cancer Family Registry (CCFR). Tumor DNA was extracted from formalin fixed paraffin embedded (FFPE) or fresh frozen tissue. Normal tissue DNA was extracted from blood or normal surrounding colorectal tissue. We designed probes for the bacterial pathogens enterotoxigenic Bacteroides fragilis (ETBF), polyketide synthase positive E. coli (pks+ EC), and Fusobacterium nucleatum (Fn). We used logistic regression to assess tumor-associated bacteria and clinical parameters, tumor molecular characteristics, and tumor stage adjusted for age, sex, and study and a Cox promotional hazard to assess association with CRC-specific survival, overall and in eoCRC, adjusted for age at diagnosis, sex, mutational burden, and microsatellite instability (MSI) and stratified baseline hazards by study. Survival data were available for 2357 and 308 patients, overall and in eoCRC, respectively. Results: The prevalence of different bacteria in tumors differed slightly overall vs. in eoCRC tumors: ETBF (5.2%, 6.3%), pks+ EC (12.9%, 14.8%), and Fn (10.4%, 8.2%). Overall, men had a lower probability of tumors with Fn (odds ratio (OR)=0.8, 95% confidence interval (CI)=0.64-0.99, p=0.04) but higher odds of tumors with pks+ EC (OR=1.38, CI=1.14-1.68, p=0.001), compared to women. The odds of prevalent Fn were higher for proximal vs distal tumors (OR=1.76, CI=1.38-2.26, p<0.001), but there was no association between tumor site and pks+ EC or ETBF. MSI-high tumors were more likely to carry Fn (OR=2.79, CI=2.08-3.75, p<0.001) and less likely to carry pks+ EC (OR=0.63, CI=0.44-0.88, p=0.008) when compared to patients with MSS tumors. In patients with non-hypermutated tumors, we observed that pks+ EC positive tumors were associated with better CRC-specific survival (HR=0.73, CI=0.57-0.93, p=0.01), whereas ETBF positive tumors (HR=1.99, CI=1,18-3.36,p=0.009) and Fn positive tumors (HR=1.33, CI=1.04-1.72, p=0.03) were associated with poorer survival. In eo-CRC patients, Fn positive status was associated with poorer survival (HR=2.4, CI= 1.056 - 5.492, p=0.026). Conclusions: We showed that the intra-tumoral microbiome differs in distribution across patient populations and patient survival over all age groups and, specifically, in eoCRC. Citation Format: Meredith A. Hullar, Keith R. Curtis, Tabitha Harrison, Yi Lin, Robert Steinfelder, Sonja I. Berndt, Daniel D. Buchanan, Andrew T. Chan, David A. Drew, Jane Figueiredo, Amy J. French, Tabitha A. Harrison, Mark A. Jenkins, Johannes Melaku, Victor Moreno, Tomotaka Ugai, Shuji Ogino, Conghui Qu, Chenxu Qu, Steven Thibodeau, Syed Zaidi, Amanda I. Phipps, Ulrike Peters, on behalf of GECCO and CCFR investigators. Evaluation of intra-tumoral pks+ E. coli, enterotoxigenic B. fragilis and Fusobacterium nucleatum, overall and in early onset disease, in colorectal cancer cases [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3039.